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DOI 10.1016/j.ccr.2009.12.034SUMMARYOncogenic fusion proteins are capable of initiating tumorigenesis, but the role of their wild-type counterparts
in this process is poorly understood. The mixed lineage leukemia (MLL) gene undergoes chromosomal
translocations, resulting in the formation of oncogenic MLL fusion proteins (MLL-FPs). Here, we show that
menin recruits bothwild-typeMLL and oncogenicMLL-AF9 fusion protein to the loci ofHOX genes to activate
their transcription.Wild-typeMLL not only catalyzes histonemethylation at key target genes but also controls
distinct MLL-AF9-induced histone methylation. Notably, the wild-type Mll allele is required for MLL-AF9-
induced leukemogenesis and maintenance of MLL-AF9-transformed cells. These findings suggest an essen-
tial cooperation between an oncogene and its wild-type counterpart in MLL-AF9-induced leukemogenesis.INTRODUCTION
Multiple oncogenic fusion proteins resulting from chromosomal
translocations are capable of initiating tumorigenesis, but little
is known about the role of the remaining wild-type (WT) allele
in this process. The mixed lineage leukemia gene (MLL) is fused
with one of over 60 distinct partner genes through chromosomal
translocations in various human acute leukemias, resulting in the
formation of multiple MLL fusion proteins (MLL-FPs) (Hess,
2004; Krivtsov and Armstrong, 2007). MLL-FPs are capable of
leukemic transformation and dysregulation of multiple Hox
genes, including Hoxa9. In one well-characterized example,
MLL-AF10 directly interacts with Dot1L, the only known
H3K79-specific methyltransferase, via the AF10 moiety and
recruits Dot1L to the Hoxa9 locus to aberrantly increase
H3K79 dimethylation (Okada et al., 2005). The H3K79 methyl-
transferase activity of Dot1L is required for enhanced transcrip-
tion of certain Hox genes and for MLL-AF10-induced bone
marrow (BM) transformation. MLL-AF4 also enhances Dot1L-Significance
The potential role of wild-type (WT) MLL in the development of
refractory to therapy, has been elusive. We demonstrate a cru
distinct MLL-FPs, in MLL-AF9-induced leukemogenesis. WT
gene expression as well as growth and survival of MLL-AF9-
importance of WT MLL in the development of MLL-AF9-induc
148 Cancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc.mediated H3K79 methylation at Hox genes (Krivtsov et al.,
2008) and theWT counterparts of additional MLL fusion partners
such as AF4 and ENL have been shown to interact with Dot1L in
a large protein complex (Bitoun et al., 2007; Mueller et al., 2007),
illustrating one common mechanism for transformation.
WT MLL is homologous to the Drosophila trithorax gene,
a positive regulator of gene expression.WTMLL is proteolytically
cleaved into two parts, MLL-N and MLL-C, by the protease Tas-
pase 1 (Hsieh et al., 2003). MLL-C contains a conserved SET
domain (Suv3-9, Enhancer of zeste and Trithorax), which cata-
lyzes histone H3 lysine 4 (H3K4) methylation and upregulates
transcription of HOX genes in fibroblasts or epithelial cell lines
(Milne et al., 2002; Nakamura et al., 2002). H3K4 trimethylation
(H3K4m3) is associated with euchromatin and active genes
and specifically recruits chromatin-remodeling proteins to
stimulate gene expression (Berger, 2007; Flanagan et al., 2005;
Li et al., 2006).
WTMLL forms a large complex with several proteins including
menin (Hughes et al., 2004; Yokoyama et al., 2005), a nuclearmixed lineage leukemia, which is highly aggressive and often
cial role for WT MLL, the common WT precursor of over 60
MLL influences MLL-AF9-induced histone methylation and
transformed leukemia cells. These findings underscore the
ed acute leukemia.
Figure 1. Menin Is Required for Both H3K4
Trimethylation and H3K79 Dimethylation at
Hoxa9 in MA9-Transformed Cells
(A) Western blot for menin in control or Men1
excised MA9-transformed AT1 cells, which
harbored Men1f/f;Cre-ER. The cells were treated
with either control DMSO (Men1f/f) or 4-OHT
(Men1D/D) to excise the floxed Men1.
(B–D) ChIP assay, with two distinct amplicons,
for detecting dimethylated H3K79 (B), trimethy-
lated H3K4 (C), and menin binding (D) at Hoxa9
in Men1f/f and Men1D/DAT1 cells. Error bars
denote ± SD.
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Wild-Type Mll Controls MLL-AF9-Induced LeukemogenesisDNA-binding protein that is mutated in an inherited human endo-
crine tumor syndrome (La et al., 2004). Menin interacts with the N
terminus of both MLL and MLL-FPs (Yokoyama et al., 2005),
increases H3K4 trimethylation (H3K4m3) at the Hoxa9 locus,
and upregulates its transcription in MLL-FP-transformed hema-
topoietic cells (Chen et al., 2006; Yokoyama et al., 2005). More-
over, menin is required for proliferation of cells transformed by
MLL-AF9 fusion protein (MA9 hereafter) (Chen et al., 2006).
However, little is known as to whether menin affects MA9-regu-
lated H3K79 methylation and whether WT MLL is important for
MA9-mediated leukemic transformation.
The potential role (or lack thereof) of WT MLL in MLL-FP-
induced leukemogenesis has not been addressed. On the one
hand, despite a lack of the WT MLL SET domain, MA9 remains
capable of initiating leukemogenesis when introduced into WT
murine or human hematopoietic progenitors (Barabe et al.,
2007; Krivtsov et al., 2006; Somervaille and Cleary, 2006; Wei
et al., 2008). Moreover, MLL-AF10 reduces H3K4 dimethylation
at theHoxa9 locus (Okada et al., 2005), which ismediated at least
partly by WT MLL. Furthermore, in MLL-FP-expressing human
leukemia cells, which in theory lose one of the twoWTMLL alleles
in chromosomal translocation, expression of WT MLL target
genes such as Hoxa9 is even higher than in non-MLL-FP-
leukemia cells (Armstrong et al., 2002). These studies raise the
possibility that WT MLL is not crucial for oncogenic transforma-
tion by MLL-FPs. On the other hand, WT MLL is crucial for
H3K4 methylation and expression of HOX genes in fibroblasts
and HeLa cells (Milne et al., 2002; Nakamura et al., 2002). More-
over, WT Mll excision compromises the function of hematopoi-
etic stemcells (HSCs) and expression of 50 Hoxa genes, including
Hoxa9 (Jude et al., 2007; McMahon et al., 2007), yet these Hox
genes are upregulated in an MA9-transformed leukemia stem
cell (LSC)–enriched population (Krivtsov et al., 2006), raising
the possibility thatWTMLL is involved inMA9-induced leukemo-
genesis. Therefore, whether the WT MLL allele is crucial for
MA9-induced leukemogenesis remains unresolved.Cancer Cell 17, 148–159,A long list of oncogenic fusion proteins
resulting from chromosomal transloca-
tions has been identified in various
leukemias and solid cancers (Nambiar
et al., 2008). However, it is poorly under-
stood whether the WT alleles influence
tumorigenesis induced by the majority
of the known oncogenic fusion proteins.A better understanding of the function of these WT alleles in
tumorigenesis could yield insights into the mechanisms of trans-
formation. Our earlier findings on the role of menin in proliferation
and gene transcription of MA9-transformed cells prompted us to
investigate the potential role of WT MLL in MA9-induced leuke-
mogenesis.
RESULTS
Menin Is Required for Methylation of Both Histone H3
Lysine 4 and Histone H3 Lysine 79 at the Hoxa9 Locus
TheMLL-AF10 fusion protein has been reported to transformBM
by increasing Dot1L-catalyzed H3K79 methylation but repres-
sing histone H3 lysine 4 (H3K4) methylation at the Hoxa9 locus,
suggesting that histone H3 lysine 79 (H3K79)-methylating
Dot1L, but not H3K4-methylating WT MLL, is crucial for MLL-
FP-induced leukemic transformation (Okada et al., 2005).
Although menin interacts with the N terminus of WT MLL and
MLL fusion proteins (Yokoyama et al., 2005), little is known as
to whether menin is crucial for H3K79 methylation at Hoxa9 in
MA9-transformed BM cells. To address this question, we
excised the floxed Men1 gene in MA9-transformed BM cells
(AT1 cells), which harbor Men1f/f;Cre-ER, using 4-hydroxyl
tamoxifen (4-OHT) to induce Cre activity (Figure 1A, lane 2).
We performed chromatin immunoprecipitation (ChIP) assays
with the control and Men1-excised cells. Our results showed
that Men1 excision reduced H3K79 dimethylation in two sepa-
rate locations at the Hoxa9 locus, as shown by amplicons a
and b (Figure 1B). As Dot1L is the only known H3K79 methyl-
transferase in mammals, this finding is consistent with the notion
that menin is crucial for MA9-induced Dot1L recruitment to the
Hoxa9 locus and H3K79 methylation at the locus.
We also noted that Men1 excision reduced H3K4 trimethyla-
tion atHoxa9 (Figure 1C), in agreement with our previous findings
(Chen et al., 2006). However, this finding is different from the
proposed role of MLL-AF10 in reducing H3K4 methylation atFebruary 17, 2010 ª2010 Elsevier Inc. 149
Figure 2. WTMLL andMA9 Are Recruited to
Hoxa9 in a Menin-Dependent Manner
(A and B) AT1 cells were treated with either DMSO
(Men1f/f) or 4-OHT (Men1D/D) and processed
for ChIP assay with either (A) anti-MLL-C or (B)
anti-AF9 C terminus antibodies.
(C) THP-1 cells were transduced with either
control scrambled or MEN1 shRNA-expressing
lentiviruses and were used for ChIP assay with
anti-AF9 or anti-Dot1L antibodies. Error bars
denote ± SD. See also Figure S1.
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesisthe Hoxa9 locus (Okada et al., 2005), which could be at least
partly mediated by WT MLL. As a control, ChIP assays showed
that menin bound the promoter of Hoxa9, and menin binding
was abrogated in Men1D/D cells (Figure 1D). Together, these
results demonstrate that menin is crucial not only for H3K4meth-
ylation but also for Dot1L-mediated H3K79 methylation at the
Hoxa9 locus in the MA9-transformed cells. These results raise
the possibility that WT MLL is crucial for MA9-induced Hox
gene expression.
Menin Recruits Both WT MLL and MA9
to the Hoxa9 Locus
To explore whether WT MLL participates in upregulating Hox
gene expression in MA9-transformed cells, we first examined
whether WT MLL binds the Hoxa9 locus, and, if so, whether
WT MLL binding to the locus depends on menin in MA9-trans-
formed BM cells. Because MA9 lacks the MLL-C portion of WT
MLL, detection of MLL-C at the Hoxa9 locus indicates that WT
MLL is recruited to the locus. Hence, we chose to use an anti-
body that specifically recognizes only MLL-C to detect WT
MLL. ChIP assays showed that MLL-C bound the Hoxa9 locus
(Figure 2A), but the MLL-C binding was abrogated when Men1
was excised (Men1D/D) in the MA9-transformed BM cells
(Figure 2A). These results indicate that menin is required for
recruiting WT MLL to Hoxa9 in the MA9-transformed cells.
Because menin interacts with the N terminus of MLL (Yo-
koyama et al., 2005), we determined whether menin affects
recruitment of MA9 (which contains the N terminus of MLL) to
Hoxa9 by ChIP assay, using an anti-AF9 antibody that recog-
nizes the AF9 portion of the MA9 fusion protein (Figure 2B).150 Cancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc.Our results indicate that MA9 bound to
Hoxa9 and that Men1 excision reduced
MA9 binding to the locus (Figure 2B).
Because the C-terminal portion (aa 397–
557) of AF9 has been reported to bind
Dot1L (Zhang et al., 2006), we tested
whether the AF9 part of MA9 bound
Dot1L using a GST-AF9 pull-down assay
and found that the AF9 portion from MA9
bound Dot1L (see Figures S1A–S1C
available online). To further evaluate
whether menin affects recruitment of
MA9 to the Hoxa9 locus in MA9-express-
ing human leukemia cells, we knocked
down menin expression, using lentivi-
ruses expressing MEN1 shRNAs, inTHP-1 cells that harbor MA9 (Figures S1D and S1F). MEN1
knockdown (KD) reduced the number of THP-1 cells
(Figure S1E),HOXA9 expression (Figure S1F), andmenin binding
to the HOXA9 locus (Figure S1G). Consistently, MEN1 KD also
reduced the binding of both MA9 and Dot1L to the HOXA9 locus
(Figure 2C). Together with data from Figure 1, these results
indicate that menin promotes recruitment of both WT MLL and
MA9/Dot1L to the HOXA9 locus, thereby increasing WT MLL-
mediated H3K4 methylation and Dot1L-mediated H3K79 meth-
ylation at the locus, respectively.
WT MLL Is Required for Proliferation and Survival
of MA9-Transformed Leukemia Cells
and for Expression of HOX Genes
It has been unresolved whether WT MLL is crucial for MLL-FP-
induced leukemia. On the one hand, H3K4 methylation, which
is at least partly mediated by WT MLL, is repressed in MLL-
AF10-transformed cells (Okada et al., 2005). On the other
hand, WT MLL is crucial for H3K4 methylation and expression
of HOX genes (Milne et al., 2002; Nakamura et al., 2002), some
of which are crucial for BM transformation by certain MLL-FPs
(Ayton and Cleary, 2003). Our data indicate a crucial role for me-
nin in WT MLL recruitment to and H3K4 methylation at HOXA9
(Figures 2A and 1C). Thus, we examined whether WT MLL is
important for expression of HOX and cell cycle genes and for
growth of MA9-transformed BM cells. We transduced AT1 cells
with either control scrambled or MLL-C-targeting shRNA retrovi-
ruses (Figure 3A, shRNA 11). The rationale for targeting only the
C terminus is to avoid affecting the mRNA encoding MA9, which
lacks the MLL-C sequence. The MLL-C shRNAs, but not the
Figure 3. WT Mll Is Required for Growth of MA9-Transformed Leukemia Cells and Expression of HOXA9 and CCNA2
(A) A diagram for the structure of WT MLL, MA9 fusion protein, and shRNAs targeting various parts of MLL-C but not MA9.
(B–D) AT1 cells were transduced with either vector or MLL-C shRNA 11 retroviruses and were monitored for cell number (± SD) (B); WTMll, Hoxa9, and cyclin A
(CCNA2) mRNAs (± SD) (C); and the protein levels of MLL-C and cyclin A (D). THP-1 cells were transduced with either control scrambled shRNA lentiviruses
(Scram) or MLL-C shRNAs.
(E–H) The resulting cells weremonitored for change in number (± SD) (E); themRNA levels ofWTMll,Hoxa9, andCCNA2 (± SD) (F); and the protein levels ofMLL-C
and cyclin A (G); MLL-N, MLL-AF9 (MA9), and menin (H). See also Figure S2.
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesisscrambled vector, reduced the number of AT1 cells (Figure 3B)
and the mRNA levels of WT Mll, Hoxa9, and Ccna2, which
encodes cyclin A2 (referred to as cyclin A hereafter) (Figure 3C),
and the MLL-C and cyclin A proteins (Figure 3D).
To determine whether WT MLL is also crucial for proliferation
of human MA9-expressing leukemia cells, we knocked down
WT MLL in THP-1 cells by transducing lentiviruses expressing
shRNAs that targeted the C terminus of human and murine
MLL (Figure 3A). Two independent MLL-C shRNAs, but not the
control shRNA, reduced the number of THP-1 cells (Figure 3E).
We also detected an increased percentage of dead cells from
WT MLL knockdown (KD) THP-1 cells (Figure S2). As expected,
WT MLL expression in the shRNA-transduced cells was
reduced, as shown by qRT-PCR and western blotting (Figures
3F and 3G). The protein level of MLL-N was also reduced;
however, the menin and MA9 levels were not affected
(Figure 3H). The expression of HOXA9 and CCNA2 was also
reduced in WT MLL KD cells (Figures 3F and 3G). Collectively,
these results indicate that WT MLL upregulates expression of
HOXA9 and CCNA2 as well as promoting proliferation and
survival of the human leukemia cells.CTo further confirm the impact of WT Mll on primary MA9-
transformed BM cells, we used a genetically tractable mouse
model to specifically excise the WT Mll gene. We bred the
Mllf/f mice (Jude et al., 2007) with ubc9-Cre-ERmice (Ruzankina
et al., 2007) and demonstrated efficient Mll excision that was
induced by 4-hydroxyl tamoxifen (4-OHT) in splenocytes from
the Mllf/f;Cre-ER mice (Figures 4A and 4B). Mll excision after
BM cells were transformed with MA9-expressing retroviruses
reduced the number of the MA9-transformed BM cells
(Figure 4C) and the expression of Hox genes in these cells
(Figure 4D), whereas 4-OHT did not affect proliferation of
MA9-transformed cells that did not express Cre-ER (Figures
S3A and S3B). Together, these experiments demonstrate that
WT MLL is important for proliferation and survival of MA9-trans-
formed leukemia cells and for high-level expression of HOX
genes in these cells.
WT MLL Is Crucial for Maximal Methylation
of Both H3K4 and H3K79 at the Target Genes
On the one hand, the SET domain of WT MLL methylates H3K4
yet is deleted fromMA9 fusion protein (Milne et al., 2002). On theancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc. 151
Figure 4. WT Mll Excision Reduces the Number of
MA9-Transformed Cells and Hox Gene Expression
(A) A diagram for the floxedMll and the primers used to detect
the intact or excised Mll.
(B) 4-OHT induced excision of the floxedMll. Spleen cells from
a Mllf/f;Cre-ER mouse were cultured with either DMSO or
4-OHT; this was followed by isolation of the genomic DNA
and PCR amplification.
(C) A growth curve for MA9-transformed BM cells with either
Mllf/f or MllD/D (± SD, cells seeded in triplicate).
(D) Quantification ofHoxa9 andHoxa5mRNAs in eitherMllf/f or
MllD/D MA9-transformed cells (± SD). See also Figure S3.
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesisother hand, loss of menin, an MLL-interacting protein, reduced
H3K4methylation atHoxa9 inMA9-transformed cells (Figure 1C).
It has been unclear whether the remaining WT MLL allele in
human MA9-expressing leukemia cells is still crucial for H3K4
methylation. We performed ChIP assays with control and WT
MLL KD THP-1 cells. WT MLL KD reduced MLL-C binding to
HOXA9 (Figure 5A), indicating that WT MLL is recruited to its
targets in the leukemia cells.
We have shown that menin is crucial for both H3K4 and H3K79
methylation at the Hoxa9 locus (Figure 1) through recruiting WTFigure 5. WT MLL Is Crucial for Maximal Methylation of Both H3K4
and H3K79 at Key Target Genes
THP-1 cells were transduced with either control scrambled shRNA or MLL-C
shRNA 14 lentiviruses to knock down WT MLL and were evaluated with
ChIP assay for MLL-C binding to Hoxa9 (A) and for histone H3K4m3 and
H3K79m2 at HOXA9 (B) and CCNA2 (C). The specificity of the anti-H3K4m3
antibody and the anti-H3K79m2 were confirmed using specifically modified
peptides and Western blot. Error bars denote ± SD. See also Figure S4.
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counterparts of several MLL fusion partners, such
as AF4, AF9, and ENL, interact with each other as
well as with Dot1L in a transcription-activating
complex (Bitoun et al., 2007; Mueller et al., 2007).However, because WT MLL is not known to directly interact
with the WT proteins of its fusion partners, it remains elusive
whether WT MLL is important for MA9/Dot1L-mediated H3K79
methylation. Notably, H3K79 methylation was also reduced at
the HOXA9 locus in these WT MLL KD cells (Figure 5B), indi-
cating a role for WT MLL in MA9/Dot1L-mediated H3K79 meth-
ylation. Similarly, WT MLL is also required for maximal methyla-
tion of both H3K4 and H3K79 at the CCNA2 locus (Figure 5C),
reinforcing the role of WT MLL in both H3K4 and H3K79 methyl-
ation. Collectively, these results suggest that WT MLL is crucial
for maximal expression of both HSC- enriched HOX genes and
proproliferating cell cycle genes, such as CCNA2, probably re-
flecting a dual role in regulating the self-renewal and proliferation
of MA9-transformed LSCs.
Ablation or Knockdown of WT MLL Reduces Colony
Formation of MA9-Transduced BM
Regulation of H3K79methylation byWTMLL raised an intriguing
possibility that WT MLL is important for transformation of BM by
MA9 or maintenance of MA9-transformed cells. We examined
the impact of WT MLL knockdown on colony formation of
MA9-transduced BM using a colony formation assay. Plating
of MLL-ENL-transduced BM in a semisolid medium for three
consecutive rounds leads to immortalization and transformation
of the hematopoietic progenitors (Lavau et al., 1997). To examine
the impact of WT MLL KD on MA9-induced BM transformation,
we transduced either the control shRNA or each of the two
MLL-C shRNAs into the MA9-transduced BM cells after the
second plating, followed by puromycin selection (Figure 6A).
The titers of these distinct shRNA and control lentiviruses were
comparable, and WT Mll KD was efficient in mouse cells (data
not shown). At the fourth plating, numerous colonies appeared
from the control cells (Figure 6B, Scram). However, WT MLL
KD with each of the MLL-C shRNAs reduced colony formation
from the MA9-transduced BM (Figures 6B and 6C).
To further confirm the role of WT MLL in MA9-induced colony
formation, we usedMllf/f;Cre-ERBM to exciseWTMll after trans-
formation. BM from controlMllf/f orMllf/f;Cre-ERmice was trans-
duced with MA9 retroviruses and serially replated on a semisolid
medium (Figure 7A).Mll excision induced by 4-OHT significantly
Figure 6. WT MLL Knockdown Suppresses Colony Formation of
MA9-Transduced BM
(A) Procedure for the colony formation assay. Bone marrow (BM) cells from
a C57B6 mouse were transduced with pMSCV-MA9 retroviruses and replated
in triplicate weekly in methylcellulose medium with G418. After the second
plating, surviving MA9 cells were transduced with each of the MLL-C shRNAs
(12 and 14) or scrambled vector.
(B) A summary of colony numbers for control or Mll shRNA-transduced BM.
(C) Representative colonies from the culture plates (scale bars represent
5 mm). Error bars denote ± SD.
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesisreduced the number of colonies from theMA9-transformedMllf/f;
Cre-ER BM (Figure 7B). As a control, 4-OHT failed to reduce
colony formation from MA9 Mllf/f BM (Figure 7C). Tamoxifen
(4-OHT)-induced excision of the floxed Mll in MA9-transformed
BM from the Mllf/f;Cre-ER mice was confirmed by genomic
PCR (Figure 7D, lane 2). These results indicate that the WT Mll
alleles are required for maintenance of MA9-transformed cells.
Hoxa9 and Meis1 have previously been shown to have the
ability to transform primary BM (Kroon et al., 1998). WTMll exci-
sion did not inhibit BM colony formation induced by Hoxa9/
Meis1 (Figure 7E). These results indicate that WT Mll is not
required for colony formation induced by Hoxa9/Meis1, likely
because both Hoxa9 and Meis1 are direct MLL targets and act
downstream of MLL (Guenther et al., 2005; Nakamura et al.,
2002). This finding is consistent with the notion that WT MLL is
essential for maintenance of MA9-transformed cells at least
partly through upregulating certain Hox genes.
We further examined the effect of pre-existing WTMll excision
on colony formation from normal BM as well as MA9-transduced
BM. BM fromMLLf/f; Cre-ERmice that were treated with tamox-
ifen (TAM) displayed effective excision of the floxed Mll allele
(Figure 7F, bottom) and reduction of colony formation (Figure 7F,
top). Moreover, BM with WT Mll or with previous deletion of WT
Mll was transduced with retroviruses expressing MA9 and was
plated on semisolid medium. We found that previous deletionCof WT Mll reduced colony formation at the first plating
(Figure 7G). These results, coupled with other results from
the colony formation assay, indicate that WT Mll is crucial for
survival or proliferation of BM progenitors and the maintenance
of MA9-transformed cells, but not necessarily for MA9-induced
transformation. From a standpoint of leukemia therapy, inhibiting
the maintenance of MA9-transformed cells is more important
than inhibiting MA9-induced transformation, because failure in
maintaining MLL-FP-transformed cells could lead to eradication
of the leukemia cells.
Mll Excision in MA9-Transformed Cells Inhibits
the Development of MA9-Induced Leukemia in Mice
We next determined the role of WT MLL in MA9-induced leuke-
mogenesis in mice using a xenotransplantation model. Either
scrambled vector or MLL-C shRNA-transduced THP-1 cells
were injected into NOD-SCID mice. Six weeks after transplanta-
tion, histological examination revealed that WTMLL KD reduced
leukemic infiltration in long bones and spleens (Figure S4A). The
spleens from mice injected with the control cells were signifi-
cantly larger than those of the mice injected with the WT MLL
KD cells (Figures S4B and S4C; p < 0.05). These results suggest
that WT MLL KD reduced engraftment of the human leukemia
cells.
To confirm these results, we established a mouse leukemia
model in which the floxed Mll can be excised in a temporally
controllable manner. BM from the Mllf/f;Cre-ER mice was trans-
duced with MA9 retroviruses. These transduced primary BM
cells were transplanted into lethally irradiated C57B6 3 B6.SJL
F1 mice (Figure 8A). Flow cytometry analysis of peripheral blood
demonstrated successful engraftment of MA9-transduced
donor BM (CD45.2+ only) and cotransplanted WT BM
(CD45.1+/2+) (Figure S5A). The percentage of cells expressing
CD11b or CD11b/Gr-1 (myeloid markers) was much higher
within the MA9-transduced BM (Figures S5C and S5D) than
that from the cotransplanted normal BM (Figure S5B). Overt
acute leukemia developed because obvious leukemia cell infil-
trations were detectable in various organs, including the femur,
liver, and spleen (Figures S5H–S5J).
For examining the impact of WT Mll excision on the develop-
ment of MA9-induced acute myeloid leukemia (AML), the MA9
transduced BM-transplanted mice were fed with either control
corn oil or TAM to excise the floxed Mll from MA9-transduced
cells and were monitored for peripheral white blood cell (WBC)
number, immunophenotypes of the WBCs, and survival rate of
the recipient mice (Figure 8A). The number of total peripheral
WBCs and the percentage of MA9-transduced BM-derived
CD11b+ myeloid cells were significantly lower in TAM-treated
mice than in the corn oil-fed control mice (Figures 8B and 8C;
p < 0.001 and 0.011, respectively). As a control, effective Mll
excision in peripheral WBCs in TAM-treated mice was observed
(Figure S5K, lanes 7–13).
In splenocytes from terminally ill corn oil-fed mice or TAM-fed
control mice, WT Mll excision reduced the percentage of the
cells bearing themarkers for L-GMP (Figures 8D and 8E), namely
c-kit+/Sca-1-/FcRgII/III+/CD11b+/CD34+, which have been
reported to be enriched in MA9-induced LSCs (Krivtsov et al.,
2006). WT Mll excision from the MA9-expressing cells also
significantly increased the survival rate of the recipient mice,ancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc. 153
Figure 7. WT Mll Is Required for Colony
Formation of MA9-Induced BM
(A) A flowchart for procedures of MA9-induced
transformation and 4-OHT-induced Mll excision.
(B)Mllexcision reduced thenumberofcolonies from
MA9-transduced BM from theMllf/f;Cre-ERmice.
(C) 4-OHT failed to reduce colony formation ofMA9
retrovirus-transduced BM from theMllf/f mice.
(D) Genotyping with genomic DNA showed that
4-OHT induced Mll excision in MA9-transformed
cells with the Mllf/f;Cre-ER genotype (lane 2) but
failed to induce Mll excision in MA9-transformed
BM cells with Mllf/f but without the Cre-ER trans-
gene (lane 4).
(E) WTMll excision failed to reduce Hoxa9/Meis1-
induced BM colony formation (top). 4-OHT
induced WT Mll excision in Hoxa9/Meis1-trans-
formed BM (bottom).
(F) WTMll excision reduced colony formation from
normal BM. BM from corn oil (CO) or TAM-treated
Mllf/f;Cre-ER mice was plated on methylcellulose
medium, and the colony number was scored at
the first plating (top). WT Mll was excised in BM
from TAM-treated, but not from corn oil-fed,Mllf/f;
Cre-ER mice (bottom).
(G) BM from corn oil or TAM-treated Mllf/f;Cre-ER
mice was first transduced with MA9 and then
plated on methylcellulose medium, and the colony
number was scored at the first plating. Error bars
denote ± SD.
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excision also modestly reduced the viability of cells from
CD45.2+ splenocytes (Figure S5L). Together, these results
suggest that WT Mll is crucial for the development of MA9-
induced leukemia partly through enhancing LSC proliferation
or survival.
DISCUSSION
The WTMll Allele, the Common Precursor
of All MLL-FPs, Controls MA9-Induced Leukemogenesis
Oncogenic fusion proteins resulting from chromosomal translo-
cations represent a major molecular lesion in leukemia and
certain solid tumors (Nambiar et al., 2008). Studies about these
malignant diseases are often centered on the fusion proteins
with little attention paid to the role of the cognate WT alleles in
tumorigenesis. A prevalentmodel suggests thatMLL-FPs induce
leukemogenesis by aberrantly upregulating expression of certain
50-Hoxa genes (Yokoyama and Cleary, 2008; Yokoyama et al.,
2005), partly through enhancing Dot1L-mediated H3K79 while
repressing H3K4 methylation (Okada et al., 2005). The SET
domain inWTMLLwas not thought to be crucial for MLL-FP-trig-
gered leukemogenesis, given that MLL-AF10 even suppresses
H3K4 dimethylation (Okada et al., 2005), which could be at least
partly mediated by WT MLL. Therefore, it has been unclear and
unresolved whether WT MLL plays a role in MLL-FP-mediated
leukemic transformation (Popovic and Zeleznik-Le, 2005).
We have shown that WT MLL is crucial for maximal levels of
H3K4 trimethylation at the loci of HOXA9 and CCNA2 and for
MA9-induced leukemogenesis. Although MLL-AF10 suppresses
H3K4 dimethylation, because WT MLL is able to convert dime-
thylated H3K4 (H3K4m2) to trimethylated H3K4 (H3K4m3), the154 Cancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc.repression of H3K4 dimethylation (H3K4m2) by MLL-AF10 could
actually result from increased WT MLL-mediated conversion of
H3K4m2 to H3K4m3. This explanation is consistent with the
observation that MLL-ENL induces H3K79 methylation but
does not suppress H3K4 trimethylation at Hoxa9 (Milne et al.,
2005). Additionally, in MLL-AF4-expressing human leukemia
cells, both methylated H3K4 and H3K79 are colocalized at large
chromatin domains, including the domain harboring the HOXA7
and HOXA9 loci (Guenther et al., 2008).
WT MLL may control MA9-induced leukemogenesis by facili-
tating the expression ofHOX genes and other self-renewal genes
and supporting LSC maintenance. Although WT MLL is crucial
for preventing HSCs from abnormal entry into cell cycle, it may
be particularly important for promoting proliferation and survival
of MA9 LSCs (Figures 8D and 8E), a function distinct from that in
HSCs (Jude et al., 2007; McMahon et al., 2007). Supporting this
explanation, the expression of Hoxa9 is reactivated in MA9-
transformed LSCs (Krivtsov et al., 2006), and WT MLL is crucial
for growth and survival of MA9-transformed leukemia cells
(Figures 3 and 4; Figures S2 and S5L), and for maintenance of
MA9 LSCs (Figures 8D and 8E). Therefore, both growth and
survival may represent mechanisms by which WT MLL influ-
ences MA9 transformed cells. However, our data using Hoxa9/
Meis1-mediated BM transformation suggest that this require-
ment for WT MLL can be replaced by ectopic expression of
Hoxa9/Meis1, likely because they are direct targets of MLL
and therefore, in this case, act downstream of MLL (Figure 7E).
There are over 60 distinct MLL-FPs, and further work remains
to determine whether our findings are generally applicable to
other MLL-FPs. Given that MLL-AF10 and MLL-AF4 increase
H3K79 methylation at target loci (Krivtsov et al., 2008; Okada
et al., 2005) and WT MLL is also necessary for maximal H3K79
Figure 8. WT Mll Is Required for MA9-Induced Leukemogenesis in Mice
(A) A diagram for MA9-induced leukemogenesis and WT Mll excision in mice. TAM feeding was done 3 weeks after BM transplantation.
(B) The total peripheral blood white blood cells (WBCs) in mice transplanted with MA9-transduced Mllf/f;Cre-ER BM were measured 5 weeks after corn oil or
TAM feeding.
(C) Flow cytometry analysis of peripheral blood CD11b+ MA9-transformed donor cells from transplanted mice, 5 weeks after the mice were fed with corn oil
or TAM.
(D) Flow cytometry analysis of CD45.2+ splenocytes from either terminally ill and corn oil-fedmice or TAM-fedmice to detect the percentage of c-kit high cells that
were FcRgII/III+/CD34+.
(E) A summary of the percentage of c-kit high cells that were FcRgII/III+/CD34+ from the corn oil or TAM-fed mice.
(F) TAM-inducedMll excision in transplanted MA9-transduced BM in recipient mice increased the survival rate of the mice. Kaplan Meier curve for mice (C57B6/
B6-SJL F1) transplanted with MA9-transduced Mllf/f;Cre-ER BM that were fed with either control corn oil (n = 11) or TAM (n = 7), 3 weeks after MA9 BM
transplantation.
(G) A model for menin, WT MLL, and MA9/Dot1L tripartite complex-controlled regulation of coupled yet distinct histone methylations, gene transcription,
MA9-induced LSCs, and leukemogenesis. See also Figure S5.
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesismethylation (Figure 5), it is likely that many MLL-FPs require WT
MLL for leukemogenesis. However, deletion of the WT Mll allele
does not change expression of Hoxa9 but reduces the colony
forming activity (CFU-GEMM) of mouse fetal liver cells express-
ing MLL-PTD (partial tandem duplication) (Dorrance et al., 2008).
MLL-PTD still retains the C-terminal SET domain, yet WT MLL is
silenced in patients’ leukemia cells expressing MLL-PTD (Whit-
man et al., 2005), raising the possibility that MLL-PTD-initiated
leukemia arises by a distinct mechanism.
The Mechanisms for WT MLL-Dependent Epigenetic
Regulation and MLL-AF9-Induced Leukemogenesis
We have uncovered a crucial role for the WT Mll allele in
promoting MA9-induced leukemogenesis. MA9 is insufficient
for maintaining the MA9-transformed leukemia cells without
the WT Mll allele. Rather, it depends on coexpression of theCWT Mll allele, which we have shown to upregulate not only
H3K4methylation but alsoMA9/Dot1L-mediated H3K79methyl-
ation at HOXA9. Consistent with this model, Men1 depletion
reduced recruitment of WT MLL to the Hoxa9 locus and dimin-
ished not only H3K4 methylation but also H3K79 methylation
at the locus.
These findings have revealed a link betweenWTMLL andMA9
in upregulating stem cell–related HOX genes and certain cell
cycle genes in MA9-transformed leukemia cells. These results
are consistent with a model whereby menin, WT MLL, and
MA9 converge at the loci of HOXA9 and certain cell cycle genes
such as CCNA2. Menin may recruit both WT MLL and MA9 at
these target genes to epigenetically promote their transcription,
leading to maintenance of LSCs and the development of MA9-
induced leukemia (Figure 8G). MLL is also associated with the
cyclin E locus in mouse embryonic fibroblasts (Takeda et al.,ancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc. 155
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Wild-Type Mll Controls MLL-AF9-Induced Leukemogenesis2006). WT MLL is degraded in an SCF (Skp2) and APC (cdc20)-
dependent manner at distinct phases of the cell cycle, but the
degradation of tested mutant MLL-FPs is inhibited (Liu et al.,
2007). It is unclear whether menin and MLL-FPs affect WT MLL
degradation.
Unlike the previous report that MLL-AF10 suppresses H3K4
dimethylation (Okada et al., 2005), our results indicate that WT
MLL controls not only H3K4 trimethylation but also H3K79 dime-
thylation, two distinct positive histone H3 modifications, at
HOXA9 and CCNA2 loci in MA9-transformed cells. H3K4m3
and H3K79m2 coexist at the loci of multiple active genes (Guc-
cione et al., 2006; Steger et al., 2008). It is likely that menin
recruits both WT MLL and MLL-FP/Dot1L, which can trimethy-
late H3K4 and dimethylate H3K79, respectively, because menin
physically interacts with the N terminus of both WT MLL and
MLL-FPs (Yokoyama et al., 2005). A combination of H3K4m3
andH3K79m2may cooperatively activate transcription of certain
HOX genes and cell cycle genes, triggering leukemic transforma-
tion and supporting the maintenance of LSCs (Figure 8G).
In agreement with this model, MLL-AF4 binds chromatin
regions that are also rich in H3K4m3 and H3K79m2 in human
leukemia cells (Guenther et al., 2008). Given that H3K4m3 is a
mark of transcriptional initiation and H3K79-methylating Dot1L
is a component of a transcriptional elongation complex, WT
MLL and menin may be crucial for regulating the key steps in
enhancing expression of HOX genes and other targets that are
important for MLL-FP-induced leukemogenesis. The protein
LEDGF also interacts with both menin and the N terminus of
MLL to facilitate their recruitment to chromatin (Yokoyama and
Cleary, 2008), but it is unclear whether the function of this protein
is regulated by menin or WT MLL.
It remains unclear howWTMLL controls H3K79 dimethylation.
Several WT counterparts of MLL fusion partners, such as AF4,
AF9, and ENL, form a transcriptional elongating complex
containing RNA polymerase II transcription elongation factor b
(P-TEFb) and Dot1L to increase gene expression (Bitoun et al.,
2007; Mueller et al., 2007; Zeisig et al., 2005). It is unknown
whether WT MLL is also in this complex and crucial for the func-
tion of this transcription elongation complex or Dot1L-mediated
H3K79 methylation. We have found that WT MLL influences
H3K79 dimethylation at the Hoxa9 gene, and it is possible that
the SET-domain or SET-mediated H3K4 methylation are impor-
tant for the role of WT MLL in MA9-induced leukemogenesis. In
this regard, methylated H3K4 serves as a docking site to recruit
various transcription-activating proteins, such as WDR5 and
BPTF (Wysockaet al., 2005;Wysockaet al., 2006).Given thatme-
nin influences WT MLL recruitment and H3K4 trimethylation, as
well as Dot1L recruitment (Figures 2A and 2C), it cannot be ruled
out that H3K4m3-binding proteins may also affect the recruit-
ment or activity of Dot1L and subsequent H3K79 methylation.
Contrary to WT MLL-dependent H3K79 dimethylation at
HOXA9, H3K4 trimethylation does not appear to rely on Dot1L-
mediated H3K79 methylation. MLL-ENL enhances H3K79 dime-
thylation at Hoxa9 but is dispensable for H3K4 trimethylation at
the locus (Milne et al., 2005). Moreover, Dot1L ablation from cells
abrogates H3K79 dimethylation but does not affect H3K4 trime-
thylation (Steger et al., 2008), suggesting a unidirectional order of
H3K4 and H3K79 methylation that is controlled by WT MLL
(Figure 8G).156 Cancer Cell 17, 148–159, February 17, 2010 ª2010 Elsevier Inc.WT MLL as a Potential Target for Leukemia Therapy
Our findings demonstrate that WT MLL is crucial for maximal
expression of HOXA9 and MA9-induced leukemogenesis. One
may argue that if the WT MLL allele is required for MLL-FP-
induced leukemogenesis, then what is the benefit for the
leukemia cells to cripple one of the two WT MLL alleles to
generate anMLL-FP? One likely explanation is that, for instance,
MA9 or MA9-induced H3K79 dimethylation cooperates with WT
MLL or WT MLL-mediated H3K4 trimethylation in activation of
HOX genes and epigenetic chromatin reprogramming, offsetting
the loss of one of the two WTMLL alleles. This is consistent with
the findings that WTMLL andMA9 target genes,HOX genes, are
expressed at a higher level in MLL-FP-expressing human
leukemia cells than in non-MLL-FP-expressing human leukemia
cells (Armstrong et al., 2002). Moreover, WT MLL may also
regulate genes controlling proliferation and self-renewal in
MA9-transformed leukemia cells or LSCs.
The necessity for WT MLL in multiple processes of leukemo-
genesis, including MA9/Dot1L-mediated H3K79 dimethylation
at HOX genes and maintenance of MA9-expressing LSCs, could
render MA9-harboring leukemia cells selectively sensitive to
inhibition of WT MLL. Despite the demonstration that MLL is
crucial for HSC and progenitor maintenance (Jude et al., 2007),
another Mll knockout model does not display obvious defects
in homeostatic hematopoiesis (McMahon et al., 2007). It is
possible that MLL-FP-expressing leukemia cells may become
particularly ‘‘addicted’’ to WT MLL for expression of stem cell–
related HOX genes and certain cell growth– and survival-related
genes. This ‘‘addiction’’ may be attributable to the reduced
cellular WT MLL levels in human leukemia cells that, in theory,
result from disruption of one WT MLL allele in chromosomal
translocation. In agreement with this interpretation, in murine
HSCs harboring endogenous knockin MA9, the amount of WT
MLL is only half that found inWT HSCs (Chen et al., 2008). More-
over, WT MLL may also be more crucial to the MLL-FP-express-
ing leukemia cells because these cells rely on WT MLL for MLL-
FP-induced H3K79 dimethylation and gene transcription
(Figure 8G). However, it cannot be ruled out that WT MLL is
also crucial for transformation induced by non-MLL-FPs.
Collectively, our findings support development of strategies to
treat MLL-FP-induced leukemia, in part by targeting the pathway
of menin and WT MLL, the common WT allele of over 60 MLL-
FPs. WT MLL may well serve as a ‘‘nononcogene addiction’’
target for treating MLL-FP-expressing leukemia (Solimini et al.,
2007). These studies raise the possibility for developing lead
compounds that specifically inhibit WT MLL, its interacting
proteins, processing enzymes, or its methyltransferase activity
to treat MLL-FP-induced acute leukemia.EXPERIMENTAL PROCEDURES
Plasmids and Cell Culture
Various plasmids were as described elsewhere: pMX-GFP, pMX-puro, pMX-
puro-menin, pMSCV-MLL-AF9 (MA9), pMSCVpgk-Hoxa9-GFP, pMSCVpac-
Meis1A, and pMSCV-GFP (Chen et al., 2006; Jin et al., 2003). Retroviral or
lentiviral constructs expressing shRNAs were obtained from Open Biosys-
tems: retroviral constructs for mouse shRNAs, pshRNA 11-MLL-C (mouse,
50-gctggcctcccataatttat-30), and lentiviral constructs expressing MLL-C
shRNAs-12 and 14 (50-cgcggtattatcctaatttaa-30 and 50-cgccttcacttgacca-
taatt-30) were highly conserved between the mouse and human WT MLL
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Wild-Type Mll Controls MLL-AF9-Induced LeukemogenesismRNAs. pLKO.1 vector (Scram) was from Sigma. Lentiviral packaging plas-
mids, pMD2G and pAX2G, were purchased from Addgene.
HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% Pen/Strep. AT1 cells were generated from BM cells of
Men1f/f;Cre-ER mice by transduction with retroviruses expressing MA9 and
cultured in medium with 10 ng/ml IL3 (Chen et al., 2006). In MA9-transformed
BMcells,Men1f/f orMllf/fwas excised by treating the cells with 4-OH tamoxifen
(4-OHT, 200 nM). THP-1 cells were maintained in RPMI-1640 containing 10%
FBS and 1% Pen/Strep supplemented with 0.05 mM 2-mercaptoethanol.
Packaging of Recombinant Retroviruses and Lentiviruses
and Transduction of Cells
pMX-GFP, pMX-puro, and pshRNAs were cotransfected with psi-2 helper
plasmid into 293T cells using the calcium chloride precipitation method, as
described elsewhere (Jin et al., 2003). For packaging lentiviruses, lenti-GFP,
scrambled pLKO.1 vector or specific pshRNAs were cotransfected into
293T cells with pAX2G and pMD2G, using Fugene-mediated transfection.
The resulting recombinant retro- or lentiviruses were collected for transduction
of cells by spinoculation, followed by selection in 2 mg/ml puromycin for 2 days.
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from the cultured cells with Trizol and an RNeasy
extraction kit (QIAGEN) and was used as template (1 mg) to synthesize cDNA
for quantitative RT-PCR (qRT-PCR) analysis in a 7500 fast real-time PCR
system (Applied Biosystems). Relative mRNA levels of a specific gene were
calculated byD-D-CT values calibratedwith either GAPDH or beta-actin, using
SYBR green dye for detection (QIAGEN, QuantiTect SYBR Green Mastermix).
The sequences of primers for qRT-PCR are listed in Supplemental Experi-
mental Procedures.
Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assay was performed as described elsewhere, with a Quick ChIP kit
(Imgenex) (Chen et al., 2006; Yan et al., 2006). In brief, cells (106) were fixed
with 1% formaldehyde and lysed in ChIP lysis buffer with protease inhibitors.
The genomic DNA was incubated with either control IgG or a specific primary
antibody at 4C overnight, and collected with protein G agarose beads. The
protein-DNA complexes were eluted from the beads and incubated at 65C
overnight for reversal of the protein-DNA crosslinking. Quantity of the precip-
itated DNA was determined with qPCR (QIAGEN, QuantiTect SYBR Green
Mastermix) and normalized with the input genomic DNA. The sequences of
the primer pairs for ChIP assay are listed in the Supplemental Experimental
Procedures.
Mice and BM Transformation
All laboratory mice were maintained on a 12 hr light-dark cycle in the animal
facility at the University of Pennsylvania. All experiments on mice in our
research protocol were approved by Institutional Animal Care and Use
Committee (IACUC) of the University of Pennsylvania and were performed in
accordance with relevant institutional and national guidelines and regulations.
Mllf/fmice (in C57B6-SJL background) (Jude et al., 2007) were bred with ubc9-
Cre-ER mice (in C57B6 background) (Schnepp et al., 2006), and BM from the
mice was isolated and transformed, as described elsewhere (Chen et al.,
2006). Briefly, C57B6 mice orMllf/f;Cre-ERmice (6–8 weeks old) were injected
with 5-fluorouracil, and BM cells were collected from femurs and prestimu-
lated with a cocktail of cytokines and growth factors, as described elsewhere
(Chen et al., 2006). The cells were transduced twice with pMSCV-MA9 retrovi-
ruses by spinoculation and replated weekly in MethoCult GF M3434 medium
(StemCell Technologies) with 1 mg/ml G418. After the second plating,
surviving cells from C57B6 or Mllf/f;Cre-ER mice were transduced twice with
either scrambled control retroviruses or lentiviruses or their counterparts
expressing one of the MLL-C shRNAs. The transduced cells (2 3 104) were
seeded in a 35 mm Petri dish with methylcellulose-based medium containing
2 mg/ml puromycin and scored for colonies with > 50 cells one week after
plating. To excise the floxed Mll, MA9-transformed BM with Mllf/f;Cre-ER
were treated with either DMSO or 4-OHT (400 nM) at the fourth plating. For
in vivo Mll excision prior to the first plating, Mllf/f;Cre-ER mice were treated
with corn oil or 200 mg/kg body weight TAM to excise the floxed Mll, asCdescribed elsewhere (Schnepp et al., 2006), and then isolated BM was either
plated directly in methylcellulose or transduced with MA9 and then plated.Leukemia Induction and WT Mll Excision from Leukemic cells
in Mice
The Mllf/f mice were backcrossed with CB57B6-SJL mice (CD45.1+) for over
nine generations (Jude et al., 2007), and the mice were then bred with trans-
genic mice expressing ubc9-Cre-ER (in C57B6 background, CD45.2+) (Ruzan-
kina et al., 2007). The Mllf/f ;Cre-ER mice were intercrossed so that the Mllf/f ;
Cre-ER genotype with the CD45.2+marker could bemaintained. BM cells from
these mice were transduced with MA9-retroviruses and transplanted retro-or-
bitally into C57B6 3 C57B6-SJL F1 female mice (CD45.1+/2+, 8 weeks old,
106 cells per mouse, Taconic), together with 2.5 3 105 BM cells from an F1
mouse. The recipient mice were irradiated with 900 rad, prior to transplanta-
tion. The mice were fed with either control corn oil or tamoxifen (TAM) (Sigma)
at a dose of 200 mg/kg body weight to excise the floxed Mll. Organs from
control and leukemic mice were isolated, fixed, and processed for H&E stain-
ing and analyzed under a microscope.Flow Cytometry Analysis and Antibodies
Cells from peripheral blood, BM, or spleen were harvested for analysis of
immunophenotypes. After blocking unspecific binding with unlabeled rat
plus mouse IgG (Sigma), cells were stained on ice in PBS plus 4% FCS and
analyzed on LSR II, FACSCalibur, or FACSAria (Becton Dickinson). Files
were analyzed in FlowJo (Tree Star). Antibodies for flow cytometry analysis,
immunoblotting, and ChIP assay were described in Supplemental Experi-
mental Procedures. All the biochemical experiments, including theChIP assay,
qRT-PCR, and cell proliferation, were repeated at least twice with consistent
results.Statistical Analysis
Microsoft Excel and GraphPad Prism software was used for statistical anal-
ysis. Student’s t test was used for determining the significance of the results
unless otherwise indicated. Kaplan-Meier statistical analysis was performed
with the log rank test.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2009.12.034.ACKNOWLEDGMENTS
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